Hiroya Kobayashi Selected Research

Vaccines

2/2023	Mitogen-activated protein kinase inhibition augments the T cell response against HOXB7-expressing tumor through human leukocyte antigen upregulation.
12/2021	Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery.
1/2018	Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition.
12/2012	A naturally processed HLA-DR-bound peptide from the IL-9 receptor alpha of HTLV-1-transformed T cells serves as a T helper epitope.
7/2008	Promiscuous peptides on the nontypeable Haemophilus influenzae P6 outer membrane protein.
10/2006	Identification of human T-cell epitopes and highly immunogenic analog peptides on the non-typeable Haemophilus influenzae P6 outer membrane protein.
7/2006	Defining MHC class II T helper epitopes for WT1 tumor antigen.
10/2004	Recognition of adult T-cell leukemia/lymphoma cells by CD4+ helper T lymphocytes specific for human T-cell leukemia virus type I envelope protein.
11/2003	Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation.
10/2002	Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroya Kobayashi Research Topics

Disease

45	Neoplasms (Cancer) 02/2024 - 03/2002
10	Squamous Cell Carcinoma of Head and Neck 02/2024 - 09/2014
9	Lymphoma (Lymphomas) 07/2023 - 10/2004
6	Bites and Stings (Sting) 01/2023 - 06/2017
6	T-Cell Lymphoma (Lymphoma, T Cell) 02/2015 - 10/2004
5	Inflammation (Inflammations) 12/2023 - 04/2003
5	Breast Neoplasms (Breast Cancer) 11/2021 - 05/2005
5	Melanoma (Melanoma, Malignant) 06/2017 - 06/2007
4	Leukemia 07/2021 - 12/2005
3	Head and Neck Neoplasms (Head and Neck Cancer) 02/2024 - 12/2021
3	Colonic Neoplasms (Colon Cancer) 08/2022 - 03/2016
3	Hematologic Neoplasms (Hematological Malignancy) 01/2016 - 04/2008
3	Carcinoma (Carcinomatosis) 11/2015 - 10/2002
3	T-Cell Leukemia (Leukemia, T Cell) 12/2012 - 10/2004
3	Infections 03/2009 - 10/2006
3	Prostatic Neoplasms (Prostate Cancer) 06/2007 - 11/2003
2	Bone Resorption 03/2023 - 06/2020
2	Colorectal Neoplasms (Colorectal Cancer) 08/2022 - 06/2020
2	Neoplasm Metastasis (Metastasis) 08/2022 - 06/2009
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020 - 06/2017
2	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 12/2012 - 10/2004
2	Urinary Bladder Neoplasms (Bladder Cancer) 07/2010 - 05/2010
1	Nasopharyngeal Carcinoma 01/2024
1	Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy 04/2023
1	Cerebral Small Vessel Diseases 04/2023
1	Periodontitis 03/2023
1	Pain (Aches) 08/2022
1	Hypoxia (Hypoxemia) 08/2022
1	Carcinogenesis 08/2022
1	Thrombocytopenia (Thrombopenia) 06/2022
1	Hemorrhage 06/2022
1	Megaloblastic Anemia 06/2022
1	Hereditary Folate Malabsorption 06/2022
1	Multiple Organ Failure (MODS) 06/2022
1	Atrophy 09/2021

Drug/Important Bio-Agent (IBA)

28	Peptides (Polypeptides)IBA 02/2024 - 10/2002
28	AntigensIBA 02/2024 - 03/2002
23	EpitopesIBA 02/2024 - 10/2002
13	Proteins (Proteins, Gene)FDA Link 12/2023 - 10/2002
11	VaccinesIBA 02/2023 - 03/2002
7	LigandsIBA 07/2023 - 02/2015
7	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 12/2021 - 10/2004
6	HLA-DR Antigens (HLA-DR)IBA 08/2023 - 09/2014
6	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2023 - 06/2017
4	Protein Subunit VaccinesIBA 02/2024 - 10/2006
4	InterferonsIBA 02/2023 - 01/2018
4	Membrane Proteins (Integral Membrane Proteins)IBA 05/2010 - 10/2006
4	Messenger RNA (mRNA)IBA 03/2009 - 04/2004
3	Biomarkers (Surrogate Marker)IBA 01/2024 - 12/2016
3	Immune Checkpoint InhibitorsIBA 08/2023 - 01/2017
3	CytokinesIBA 03/2023 - 09/2014
3	HLA Antigens (Human Leukocyte Antigens)IBA 02/2023 - 06/2007
3	Neoplasm Antigens (Tumor Antigens)IBA 12/2021 - 10/2002
3	Monoclonal AntibodiesIBA 08/2021 - 04/2003
3	Interferon Type IIBA 08/2021 - 06/2017
3	ChemokinesIBA 06/2017 - 06/2015
3	HLA-DR15 antigenIBA 12/2012 - 10/2004
2	terreinIBA 03/2023 - 06/2020
2	Mitogen-Activated Protein KinasesIBA 02/2023 - 01/2022
2	Granzymes (Granzyme)IBA 02/2023 - 12/2021
2	Dinoprostone (PGE2)FDA Link 01/2023 - 09/2014
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2023 - 09/2014
2	Cancer VaccinesIBA 08/2022 - 12/2021
2	Tyrosine Kinase InhibitorsIBA 01/2022 - 11/2015
2	DNA (Deoxyribonucleic Acid)IBA 05/2021 - 06/2016
2	B7-H1 AntigenIBA 01/2019 - 07/2017
2	Histocompatibility Antigens Class IIIBA 05/2014 - 07/2006
2	HLA-DR53IBA 12/2012 - 05/2005
2	Complementary DNA (cDNA)IBA 12/2007 - 12/2005
2	AutoantigensIBA 06/2006 - 10/2004
2	HLA-DR9 antigenIBA 05/2005 - 10/2004
2	Carcinoembryonic AntigenIBA 04/2004 - 10/2002
1	Gemcitabine FDA Link 08/2023
1	Brachyury protein (Brachyury)IBA 08/2023
1	Serine (L-Serine)FDA Link 04/2023
1	Peptide Hydrolases (Proteases)FDA Link 04/2023
1	Small Interfering RNA (siRNA)IBA 02/2023
1	Celecoxib (Celebrex)FDA Link 01/2023
1	Glucose (Dextrose)FDA LinkGeneric 01/2023
1	Neurokinin AIBA 08/2022
1	Double-Stranded RNA (RNA, Double Stranded)IBA 08/2022
1	Poly I-CIBA 08/2022
1	TachykininsIBA 08/2022
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 08/2022
1	Mitogen-Activated Protein Kinase 3IBA 08/2022
1	Neurokinin-2 Receptors (Neurokinin 2 Receptor)IBA 08/2022
1	Folic Acid (Vitamin M)FDA LinkGeneric 06/2022
1	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 01/2022
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 12/2021
1	Combined VaccinesIBA 12/2021
1	nutlin 3IBA 12/2021
1	MHC class II transactivator proteinIBA 12/2021
1	CollagenIBA 09/2021
1	olmesartanIBA 09/2021
1	Angiotensin Receptor AntagonistsIBA 09/2021

Therapy/Procedure

34	Immunotherapy 02/2024 - 10/2002
16	Therapeutics 08/2023 - 04/2004
2	Drug Therapy (Chemotherapy) 01/2018 - 10/2004
1	Ligation 03/2023
1	Immunomodulation 01/2022